In vivo effects of HIV-1 exposure in the presence and absence of single-dose nevirapine on cellular plasma activation markers of infants born to HIV-1-seropositive mothers

Journal of Acquired Immune Deficiency Syndromes

Volumn 42, Issue 5, 2006, Pages 545-553

  Schramm, Diana B ^a   Kuhn, Louise ^b   Gray, Glenda E ^c   Tiemessen, Caroline T ^a,d  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b Columbia University ^*  (United States)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^d NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

Author keywords

HIV 1 seropositive mothers; Nevirapine; Newborn; Plasma immune activation markers

Indexed keywords

BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; L SELECTIN; NEOPTERIN; NEVIRAPINE; ZIDOVUDINE;

ADULT; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSTIMULATION; INFANT; LABOR; MAJOR CLINICAL STUDY; MALE; MATERNAL BLOOD; MOTHER; NEWBORN; NEWBORN INFECTION; PLACENTAL TRANSFER; PRENATAL EXPOSURE; PRIORITY JOURNAL; SINGLE DRUG DOSE; T LYMPHOCYTE ACTIVATION; UMBILICAL CORD BLOOD; VERTICAL TRANSMISSION; VIRUS REPLICATION;

ADULT; ANTI-HIV AGENTS; BETA 2-MICROGLOBULIN; BIOLOGICAL MARKERS; BLOOD CHEMICAL ANALYSIS; FEMALE; FETAL BLOOD; HIV INFECTIONS; HIV-1; HUMANS; INFANT, NEWBORN; L-SELECTIN; LYMPHOCYTE ACTIVATION; MOTHERS; NEOPTERIN; NEVIRAPINE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS;

EID: 33746666590     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000225009.30698.ce     Document Type: Article

References (40)

1. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994;331(18):1173-1180.
2. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet. 1999;354(9181):795-802.
3. Shaffer N, Chuachoowong R, Mock PA, et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Bangkok Collaborative Perinatal HIV Transmission Study Group. Lancet. 1999;353(9155):773-780.
4. Wiktor SZ, Ekpini E, Karon JM, et al. Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Cote d'Ivoire: a randomised trial. Lancet. 1999;353(9155):781-785.
5. Dabis F, Msellati P, Meda N, et al. 6-Month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Cote d'Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial. DITRAME Study Group. DIminution de la Transmission Mere-Enfant. Lancet. 1999;353(9155):786-792.
6. Jackson JB, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet. 2003;362(9387):859-868.
7. Sperling RS, Shapiro DE, Coombs RW, et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1996;335(22):1621-1629.
8. Kinoshita S, Su L, Amano M, et al. The T cell activation factor NF-ATc positively regulates HIV-1 replication and gene expression in T cells. Immunity. 1997;6(3):235-244.
9. Oswald-Richter K, Grill SM, Leelawong M, et al. HIV infection of primary human T cells is determined by tunable thresholds of T cell activation. Eur J Immunol. 2004;34(6):1705-1714.
10. Rowland-Jones S, Tan R, McMichael A. Role of cellular immunity in protection against HIV infection. Adv Immunol. 1997;65:277-346.
11. Chavan S, Kodoth S, Pahwa R, et al. The HIV protease inhibitor indinavir inhibits cell-cycle progression in vitro in lymphocytes of HIV-infected and uninfected individuals. Blood. 2001;98(2):383-389.
12. Kuhn L, Meddows-Taylor S, Gray G, et al. Reduced HIV-stimulated T-helper cell reactivity in cord blood with short-course antiretroviral treatment for prevention of maternal-infant transmission. Clin Exp Immunol. 2001;123(3):443-450.
13. Fahey JL, Taylor JM, Detels R, et al. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med. 1990;322(3):166-172.
14. Fuchs D, Hausen A, Reibnegger G, et al. Neopterin as a marker for activated cell-mediated immunity: application in HIV infection. Immunol Today. 1988;9(5):150-155.
15. Gray GE, Urban M, Chersich MF, et al. A randomized trial of two postexposure prophylaxis regimens to reduce mother-to-child HIV-1 transmission in infants of untreated mothers. AIDS. 2005;19(12):1289-1297.
16. Saji F, Samejima Y, Kamiura S, et al. Dynamics of immunoglobulins at the feto-maternal interface. Rev Reprod. 1999;4(2):81-89.
17. Borkowsky W, Krasinski K, Moore T, et al. Lymphocyte proliferative responses to HIV-1 envelope and core antigens by infected and uninfected adults and children. AIDS Res Hum Retroviruses. 1990;6(5):673-678.
18. Cheynier R, Langlade-Demoyen P, Marescot MR, et al. Cytotoxic T lymphocyte responses in the peripheral blood of children born to human immunodeficiency virus-1-infected mothers. Eur J Immunol. 1992;22(9):2211-2217.
19. Rowland-Jones SL, Nixon DF, Aldhous MC, et al. HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected infant. Lancet. 1993;341(8849):860-861.
20. Aldhous MC, Watret KC, Mok JY, et al. Cytotoxic T lymphocyte activity and CD8 subpopulations in children at risk of HIV infection. Clin Exp Immunol. 1994;97(1):61-67.
21. De Maria A, Cirillo C, Moretta L. Occurrence of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T cell activity in apparently uninfected children born to HIV-1-infected mothers. J Infect Dis. 1994;170(5):1296-1299.
22. Kuhn L, Coutsoudis A, Moodley D, et al. T-helper cell responses to HIV envelope peptides in cord blood: protection against intrapartum and breast-feeding transmission. AIDS. 2001;15(1):1-9.
23. Wasik TJ, Bratosiewicz J, Wierzbicki A, et al. Protective role of beta-chemokines associated with HIV-specific Th responses against perinatal HIV transmission. J Immunol. 1999;162(7):4355-4364.
24. Clerici M, Saresella M, Colombo F, et al. T-lymphocyte maturation abnormalities in uninfected newborns and children with vertical exposure to HIV. Blood. 2000;96(12):3866-3871.
25. Levy JA, Hsueh F, Blackbourn DJ, et al. CD8 cell noncytotoxic antiviral activity in human immunodeficiency virus-infected and -uninfected children. J Infect Dis. 1998;177(2):470-472.
26. Kuhn L, Meddows-Taylor S, Gray G, et al. HIV-stimulated IL-2 production among exposed-uninfected infants of HIV-infected mothers given nevirapine prophylaxis. Presented at: 10th Conference on Retroviruses and Opportunistic Infections; February 10-14, 2003; Boston, MA.
27. Lifson AR, Hessol NA, Buchbinder SP, et al. Serum beta 2-microglobulin and prediction of progression to AIDS in HIV infection. Lancet. 1992;339(8807):1436-1440.
28. Kourtis AP, Nesheim SR, Thea D, et al. Correlation of virus load and soluble L-selectin, a marker of immune activation, in pediatric HIV-1 infection. AIDS. 2000;14(16):2429-2436.
29. Radunovic N, Kuczynski E, Rebarber A, et al. Neopterin concentrations in fetal and maternal blood: a marker of cell-mediated immune activation. Am J Obstet Gynecol. 1999;181(1):170-173.
30. Cejka J, Kithier K, Belamaric J, et al. Feto-specific features of human beta2-microglobulin. Experientia. 1974;30(5):458-459.
31. Widner B, Wirleitner B, Baier-Bitterlich G, et al. Cellular immune activation, neopterin production, tryptophan degradation and the development of immunodeficiency. Arch Immunol Ther Exp (Warsz). 2000;48(4):251-258.
32. Xie J, Wang Y, Freeman ME 3rd, et al. Beta 2-microglobulin as a negative regulator of the immune system: high concentrations of the protein inhibit in vitro generation of functional dendritic cells. Blood. 2003;101(10):4005-4012.
33. Economides A, Schmid I, Anisman-Posner DJ, et al. Apoptosis in cord blood T lymphocytes from infants of human immunodeficiency virus-infected mothers. Clin Diagn Lab Immunol. 1998;5(2):230-234.
34. Rapid disease progression in HIV-1 perinatally infected children born to mothers receiving zidovudine monotherapy during pregnancy. The Italian register for HIV Infection in Children. AIDS. 1999;13(8):927-933.
35. Kuhn L, Abrams EJ, Weedon J, et al. Disease progression and early viral dynamics in human immunodeficiency virus-infected children exposed to zidovudine during prenatal and perinatal periods. J Infect Dis. 2000;182(1):104-111.
36. de Souza RS, Gomez-Marin O, Scott GB, et al. Effect of prenatal zidovudine on disease progression in perinatally HIV-1-infected infants. J Acquir Immune Defic Syndr. 2000;24(2):154-161.
37. Sutthent R, Chokephaibulkit K, Piyasujabul D, et al. Effect of perinatal short-course zidovudine on the clinical and virological manifestations of HIV-1 subtype E infection in infants. J Clin Virol. 2002;25(1):47-56.
38. Rich KC, Fowler MG, Mofenson LM, et al. Maternal and infant factors predicting disease progression in human immunodeficiency virus type 1-infected infants. Women and Infants Transmission Study Group. Pediatrics. 2000;105(1):e8.
39. Dabis F, Elenga N, Meda N, et al. 18-Month mortality and perinatal exposure to zidovudine in West Africa. AIDS. 2001;15(6):771-779.
40. Estelberger W, Weiss G, Petek W, et al. Determination of renal clearance of neopterin by a pharmacokinetic approach. FEBS Lett. 1993;329(1-2):13-16.